APA (7th ed.) Citation

J, W., D, H., H, Y., D, W., Y, Y., J, C., . . . J, Z. (2025). EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma. Cell death & disease, 16(1), 522. https://doi.org/10.1038/s41419-025-07775-x

Chicago Style (17th ed.) Citation

J, Wu, et al. "EZH2 Inhibitor SHR2554 Enhances the Anti-tumor Efficacy of HDAC Inhibitor Chidamide Through STAT1 in T-cell Lymphoma." Cell Death & Disease 16, no. 1 (2025): 522. https://doi.org/10.1038/s41419-025-07775-x.

MLA (9th ed.) Citation

J, Wu, et al. "EZH2 Inhibitor SHR2554 Enhances the Anti-tumor Efficacy of HDAC Inhibitor Chidamide Through STAT1 in T-cell Lymphoma." Cell Death & Disease, vol. 16, no. 1, 2025, p. 522, https://doi.org/10.1038/s41419-025-07775-x.